OncRef

Clinical Trial: NCT07358676

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:Tianjin Medical University Cancer Institute and Hospital
Information Provided By:Tianjin Medical University Cancer Institute and Hospital
Last Update Posted:2026-07-06

Study Overview

Brief Summary

This is a phase II study evaluating a new combination therapy for untreated extensive-stage small cell lung cancer. The treatment involves an initial phase with the drug Bemotuzumab plus standard chemotherapy and anlotinib, followed by a phase combining Bemotuzumab, anlotinib, and chest radiation. The primary objectives are to assess the efficacy of this approach in delaying cancer growth (progression-free survival) and to evaluate its safety in approximately 25 patients.

Official Title

An Exploratory Phase II Study of Bemotuzumab Combined With Chemotherapy and Anlotinib as Induction Therapy, Followed by Bemotuzumab, Anlotinib, and Consolidative Thoracic Radiotherapy in Patients With Extensive-Stage Small Cell Lung Cancer

Conditions

Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage

Intervention / Treatment

  • Combination Product: Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy

Other Study ID Numbers

  • E20260033

Start Date (Actual)

2026-02-01

Primary Completion Date (Estimated)

2027-01-01

Study Completion Date (Estimated)

2028-01-01

Enrollment (Estimated)

25

Study Type

Interventional

Phase

Phase 2